- Home
- PHM vs TEVA Comparison
PHM vs TEVA Comparison
Compare PHM & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHM
- TEVA
- Stock Information
- Founded
- PHM 1950
- TEVA 1901
- Country
- PHM United States
- TEVA Israel
- Employees
- PHM N/A
- TEVA N/A
- Industry
- PHM Homebuilding
- TEVA Biotechnology: Pharmaceutical Preparations
- Sector
- PHM Consumer Discretionary
- TEVA Health Care
- Exchange
- PHM Nasdaq
- TEVA Nasdaq
- Market Cap
- PHM 20.5B
- TEVA 18.4B
- IPO Year
- PHM N/A
- TEVA N/A
- Fundamental
- Price
- PHM $98.02
- TEVA $16.77
- Analyst Decision
- PHM Buy
- TEVA Strong Buy
- Analyst Count
- PHM 15
- TEVA 7
- Target Price
- PHM $132.21
- TEVA $25.14
- AVG Volume (30 Days)
- PHM 1.8M
- TEVA 14.1M
- Earning Date
- PHM 07-22-2025
- TEVA 05-07-2025
- Dividend Yield
- PHM 0.90%
- TEVA N/A
- EPS Growth
- PHM 13.61
- TEVA N/A
- EPS
- PHM 14.20
- TEVA N/A
- Revenue
- PHM $17,890,440,000.00
- TEVA $16,616,000,000.00
- Revenue This Year
- PHM N/A
- TEVA $5.69
- Revenue Next Year
- PHM $2.46
- TEVA N/A
- P/E Ratio
- PHM $6.91
- TEVA N/A
- Revenue Growth
- PHM 8.86
- TEVA 3.82
- 52 Week Low
- PHM $88.07
- TEVA $12.47
- 52 Week High
- PHM $149.47
- TEVA $22.80
- Technical
- Relative Strength Index (RSI)
- PHM 43.62
- TEVA 51.29
- Support Level
- PHM $97.39
- TEVA $16.68
- Resistance Level
- PHM $100.72
- TEVA $18.28
- Average True Range (ATR)
- PHM 2.42
- TEVA 0.63
- MACD
- PHM -0.58
- TEVA -0.04
- Stochastic Oscillator
- PHM 8.56
- TEVA 20.11
About PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.